Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia, Refractory, with Excess of Blasts 255Myelodysplastic Syndromes 228Leukemia, Myeloid, Acute 228Anemia 212Leukemia 205Precursor Cell Lymphoblastic Leukemia-Lymphoma 168Leukemia, Myelomonocytic, Chronic 145Neoplasms 142Leukemia, Lymphocytic, Chronic, B-Cell 116Myeloproliferative Disorders 114Multiple Myeloma 113Lymphoma, Non-Hodgkin 105Thrombocytopenia 100Lymphoma 98Hodgkin Disease 91Anemia, Refractory 81Venous Thromboembolism 77Congenital Abnormalities 77Anemia, Aplastic 77Primary Myelofibrosis 76Lymphoma, Follicular 73Leukemia, Myeloid, Chronic-Phase 70Blast Crisis 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65Leukemia, Myeloid, Accelerated Phase 64Lymphoma, Mantle-Cell 63Febrile Neutropenia 62Myelodysplastic-Myeloproliferative Diseases 58Hematologic Neoplasms 56Burkitt Lymphoma 56

Interventions

continuous erythropoietin receptor activator 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Renal Anemia × Classical hematology × Clear all
NCT00717366 2017-09-08

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Hoffmann-La Roche

Phase 2 Completed
64 enrolled 15 charts 1 FDA
Classical hematology

Renal Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡